RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cartesian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.08−0.19 (-3.03%)
Close on Oct 19, 2026
- Market cap
- $181.55M
- P/E (TTM)
- –
- Dividend yield
- –
Cartesian Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Market Cap | $183.95M | $166.30M |
| Enterprise Value | $89.20M | $87.12M |
| PS Ratio | 124.55 | 3.60 |
Enterprise value
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 60.39 | 2.43 |
Income (trailing twelve months)
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Revenue | $1.48M | $57.94M |
| Operating Income | -$155.36M | -$21.49M |
| Net Income | -$151.89M | -$22.46M |
| EBITDA | -$155.36M | -$17.14M |
| EPS (Diluted) | -$5.94 | -$0.83 |
Margins
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -10518.6% | -44.5% |
| Profit Margin | -10283.8% | -39.2% |
| EBITDA Margin | -10518.6% | -31.3% |
| FCF Margin | -5322.4% | -8.85% |
Returns
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -42.9% | -41.0% |
| Return on Capital Employed (ROCE) | -52.1% | -38.0% |
Growth
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -70.7% | 2.25% |
| Revenue Growth (5Y CAGR) | -30.0% | 6.42% |
Balance sheet
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $147.61M | $62.64M |
| Total Debt | $52.85M | $120.13M |
| Net Cash (Debt) | $94.76M | $15.77M |
| Net Cash Per Share | $3.13 | $0.66 |
| Equity (Book Value) | -$125.23M | $48.61M |
| Book Value Per Share | -$4.14 | $1.36 |
| Tangible Book Value | -$173.39M | $23.01M |
| Working Capital | $133.07M | $75.09M |
Financial position
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.48 | 3.30 |
| Quick Ratio | 7.19 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$76.53M | -$12.39M |
| Capital Expenditures | -$2.08M | -$1.07M |
| Free Cash Flow | -$78.61M | -$20.34M |
| FCF Per Share | -$2.60 | -$0.42 |
Efficiency
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $19.69K | $398.96K |
| Profits Per Employee | -$2.03M | -$705.27K |
| Employee Count | 75 | 74 |
Dividends and yields
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -82.6% | -22.8% |
| FCF Yield | -42.7% | -9.02% |
Shares
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 30,255,400 | 58,139,000 |
| Shares Change (YoY) | 9.20% | 11.1% |
| Shares Change (QoQ) | 5.23% | 0.54% |
| Float | 13,400,600 | 49,154,900 |
| Shares Held by Insiders | 55.7% | 11.6% |
| Shares Held by Institutions | 29.3% | 59.4% |
Scores
| Measure | Cartesian Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -4.57 | -0.27 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Cartesian Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.